Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 10/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27561346 | 0.77 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1PDE10ACYP1A2 | |
| SCHEMBL15174151 | 0.77 | MTNR1A (0.39) | MTNR1AMTNR1BGABRA1GABRG2GABRB3 | |
| SCHEMBL1996104 | 0.73 | AAK1 (0.38) | MTNR1AMTNR1BGABRA1GABRG2GABRB3 | |
| SCHEMBL25972059 | 0.72 | MTNR1A (0.56) | MTNR1AMTNR1B | |
| SCHEMBL1999697 | 0.71 | GABRA1 (0.38) | MTNR1AMTNR1BGABRA1GABRG2GABRB3 | |
| SCHEMBL14911387 | 0.71 | PDE10A (0.46) | CYSLTR2CYSLTR1PDE10A | |
| SCHEMBL27394889 | 0.71 | KDM4E (0.50) | MTNR1AMTNR1B | |
| SCHEMBL855385 | 0.70 | XPO1 (0.43) | MTNR1AMTNR1B | |
| SCHEMBL29456195 | 0.70 | MAPK8 (0.42) | MTNR1AMTNR1B | |
| SCHEMBL7808283 | 0.70 | CCR1 (0.48) | CYSLTR2CYSLTR1PDE10ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657034-B2 | Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors | AbbVie Deuschland GmbH & Co. KG (DE) | 2017-05-23 | — | — | US | disclosed |
| EP-2776418-B1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-01-04 | — | — | EP | disclosed |
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-05-19 | — | — | US | disclosed |
| US-9273068-B2 | Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-03-01 | — | — | US | disclosed |
| EP-2776418-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068470-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-05-16 | — | — | WO | disclosed |
| US-20130116241-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116233-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | CYSLTR2 2436/4885CYSLTR1 1293/4885PDE10A 5/4885 |
| US-20130116241-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | CYSLTR2 2436/4885CYSLTR1 1293/4885PDE10A 5/4885 |
| US-20130116233-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE2A | CYSLTR2 3188/4885CYSLTR1 2879/4885PDE10A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.